Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | MEN1 | O00255 | 4/20 | 0.78 |
| ▸ | NPC1 | O15118 | 4/20 | 0.76 |
| ▸ | RAB9A | P51151 | 4/20 | 0.76 |
| ▸ | MAPT | P10636 | 4/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.69 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.69 |
| ▸ | METAP2 | P50579 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | PNLIP | P16233 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721612 | 0.89 | MAPT (0.73) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL2362772 | 0.88 | KMT2A (0.82) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL4437079 | 0.88 | MAPT (0.69) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL27901571 | 0.88 | KMT2A (0.71) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL5390989 | 0.87 | MAPT (0.71) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL30739719 | 0.87 | MAPT (0.71) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL4429130 | 0.87 | MAPT (0.71) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL94630 | 0.86 | MAPT (0.69) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL4432153 | 0.86 | MAPT (0.69) | KMT2AMEN1NPC1RAB9AMAPT | |
| SCHEMBL678394 | 0.86 | MAPT (0.69) | KMT2AMEN1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1655290-B1 | Compositions comprising a benzoisothiazolone derivative and their use in the cosmetic field | OREAL (FR) | 2009-04-29 | — | — | EP | disclosed |
| US-7232839-B2 | Benzoisothiazolone compositions | L'OREAL (FR) | 2007-06-19 | — | — | US | disclosed |
| US-20060142587-A1 | Benzoisothiazolone compositions | L'OREAL (FR) | 2006-06-29 | — | — | US | disclosed |
| EP-1655290-A1 | Compositions comprising a benzoisothiazolone derivative and their use in the cosmetic field | L'OREAL (FR) | 2006-05-10 | — | — | EP | disclosed |
| US-6897316-B2 | Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents | CHINA MEDICAL UNIVERSITY (TW) | 2005-05-24 | — | — | US | disclosed |
| US-20050032832-A1 | Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents | CHINA MEDICAL UNIVERSITY (TW) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142587-A1 | Benzoisothiazolone compositions | COL1A1, TYR, CUTA | KMT2A 3462/4885MEN1 4601/4885NPC1 2766/4885 |
| US-20050032832-A1 | Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHUK | KMT2A 780/4885MEN1 3877/4885NPC1 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.